TABLE 2.

In vitro activities of selected antimicrobials against Chryseobacterium spp. according to SENTRY region

Antimicrobial agenta	Asia-West Pacific (n = 16)		Europe (n = 5)		Latin America (n = 14)		North America (n = 15)
	% Susceptible	% Resistant	% Susceptible	% Resistant	% Susceptible	% Resistant	% Susceptible	% Resistant
Gatifloxacin	100.0	0.0	100.0	0.0	92.9	0.0	100.0	0.0
Garenoxacinb	100.0	0.0	100.0	0.0	92.9	0.0	100.0	0.0
Levofloxacin	100.0	0.0	100.0	0.0	100.0	0.0	93.3	6.7
Ciprofloxacin	68.8	12.5	100.0	0.0	85.7	7.1	80.0	20.0
Trimethoprim-sulfamethoxazole	81.3	18.7	80.0	20.0d	85.7	14.3	93.3	6.7
Piperacillin-tazobactam	50.0	6.3	100.0	0.0	85.7	7.1	100.0	0.0
Piperacillin	37.5	50.1	100.0	0.0	85.7	14.3	93.3	0.0
Cefepime	18.8	62.5	100.0	0.0	64.3	14.3	93.3	0.0
Ceftazidime	12.5	87.5	100.0	0.0	57.1	42.9	53.3	40.0
Imipenem	0.0	100.0	20.0	80.0	14.3	85.7	20.0	73.3
Amikacin	6.3	81.2	20.0	0.0	14.3	28.6	20.0	26.7
Rifampinc	93.8	0.0	75.0	0.0	85.7	0.0	80.0	0.0

^aNCCLS MIC breakpoints for non-Enterobacteriaceae were categorically applied to Chryseobacterium spp. (17).

^bA susceptibility breakpoint of ≤2 μg/ml was applied (13).

^cNCCLS MIC breakpoints for Staphylococcus spp. were applied (17).

^dA C. gleum isolate had an MIC >1/19 μg/ml and was not available for retesting.